<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81905">
  <stage>Registered</stage>
  <submitdate>9/03/2007</submitdate>
  <approvaldate>15/03/2007</approvaldate>
  <actrnumber>ACTRN12607000171415</actrnumber>
  <trial_identification>
    <studytitle>Activity and Safety of SCH 532706 in HIV-1 Infected Subjects</studytitle>
    <scientifictitle>To evaluate the virologic activity of SCH 532706 coadministered with ritonavir in CCR5-tropic HIV-infected individuals.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>CCR5-tropic HIV-Infected Individuals</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This is a single-site, fixed sequence, open label, evaluation of SCH 532706 plus ritonavir. Each patient will receive 20 doses of SCH 532706 and 10 doses of ritonavir over 10 days.

SCH 532706 60mg administered twice daily as an oral solution (at 2mg/mL)

Ritonavir 100mg will be administered once daily as a single capsule.

Each patient will be given SCH 532706 morning (AM) and night and Ritonavir each morning (AM) for 10 days.</interventions>
    <comparator>No comparator.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Virologic activity; subjects will have HIV-1 viral Ribonucleic acid (RNA) values measured</outcome>
      <timepoint>Measured on study day -1 (one day prior to the first dose) and days 1, 3, 5, 7, 10, 15, 20 and 25 after the first dose.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetic profile; plasma samples for analysis will be collected.</outcome>
      <timepoint>* Day 1 and Day 10, predose that is 0 hours, and 0.5, 1, 1.5, 2, 4, 6, and 12 hours post AM dose.
* Days 3, 5, and 7, samples will be collected before the AM dose.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>* Documented HIV infection* Must have a BMI of between 19 to 35 inclusive* Must have CCR5 tropism only.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>* Female subjects who are pregnant, intend to become pregnant (within 3 months of ending the study), or are breast-feeding* Subject's with history of a seizure disorder* Subject with a mental instability.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Pharmacokinetics</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>6/03/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>12</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Schering-Plough</primarysponsorname>
    <primarysponsoraddress>2000 Galloping Hill Rd, NJ 7033</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Schering-Plough</fundingname>
      <fundingaddress>2000 Galloping Hill Rd, NJ 7033</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to assess the virologic activity, safety, tolerability and pharmacodynmaic profile of SCH 532706 when codminstered with a dose of Ritonavir that could be observed during the treatment of patients with HIV.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Sarah Pett</name>
      <address>National Centre in HIV Epidemiology and Clinical Research
Level 2
376 Victoria Street
Sydney NSW 2000</address>
      <phone>+61 2 93850900</phone>
      <fax />
      <email>spett@nchecr.unsw.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Sarah Pett</name>
      <address>National Centre in HIV Epidemiology and Clinical Research
Level 2
376 Victoria Street
Sydney NSW 2000</address>
      <phone>+61 2 93850900</phone>
      <fax />
      <email>spett@nchecr.unsw.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>